An independent evidence review released this week by the Vaccine Integrity Project and the American Medical Association confirms that influenza, RSV, and COVID-19 immunizations continue to provide strong protection against severe illness, hospitalization, and death in infants and children. No new pediatric safety concerns were identified.
Background: Why this review matters now
Respiratory virus season is underway. RSV, flu, and COVID-19 remain leading causes of infant hospitalization. In recent years, federal vaccine advisory processes have faced disruption, with the CDC’s Advisory Committee on Immunization Practices (ACIP) members dismissed and replaced. Professional societies including the American Academy of Pediatrics (AAP), AAFP, ACOG, and IDSA have continued to issue independent recommendations.
To fill the evidence gap, the Vaccine Integrity Project (based at CIDRAP, University of Minnesota) and the AMA completed a rigorous independent review of studies published primarily between August 2025 and June 2026. They screened nearly 19,000 papers and included hundreds of high-quality studies (69 on influenza, 155 on COVID-19, 75 on RSV). The findings helped shape the 2026-27 respiratory virus immunization recommendations.
What the evidence shows
Across all three, comparative studies identified no new safety signals. Post-marketing data (which lack control groups) were consistent with established safety profiles.
Competing viewpoints
Proponents of independent professional society guidance argue that the review restores evidence-based decision-making when federal processes are disrupted. Critics of broader immunization efforts continue to raise questions about long-term data, individual risk-benefit for low-risk groups, and the role of natural infection. Some parents prefer to wait for CDC-aligned guidance or seek personalized advice from their own clinicians. The review’s authors note remaining gaps, such as booster needs in older adults and the inherent limits of surveillance data without comparison groups.
What parents should watch next
Talk with your pediatrician or obstetrician about the timing that fits your household. For newborns and young infants, the combination of maternal vaccination (where available) and nirsevimab for RSV remains one of the highest-impact interventions this season. Watch for clinic availability of the updated products, any local RSV or flu activity reports, and the AAP’s full 2026-27 schedule details. The interactive study database from the Vaccine Integrity Project lets clinicians and families look up the underlying papers.
Editorial context only — not medical advice. Confirm recommendations with your care team.
Comments (0)
No comments yet.
Sign in to comment.